These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
539 related articles for article (PubMed ID: 31931137)
1. Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases. Yang JC; Schuler M; Popat S; Miura S; Heeke S; Park K; Märten A; Kim ES J Thorac Oncol; 2020 May; 15(5):803-815. PubMed ID: 31931137 [TBL] [Abstract][Full Text] [Related]
2. First-line Afatinib in Patients With Non-small-cell Lung Cancer With Uncommon EGFR Mutations in South Korea. Kim MH; Choi CM; Lee SY; Park CK; Chang YS; Lee KY; Kim SJ; Yang SH; Ryu JS; Lee JE; Lee SY; Park CK; Lee SH; Jang SH; Yoon SH; Jang TW Anticancer Res; 2022 Mar; 42(3):1615-1622. PubMed ID: 35220259 [TBL] [Abstract][Full Text] [Related]
3. Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon Yang JC; Schuler M; Popat S; Miura S; Park K; Passaro A; De Marinis F; Solca F; Märten A; Kim ES Front Oncol; 2022; 12():834704. PubMed ID: 35574304 [TBL] [Abstract][Full Text] [Related]
4. Tyrosine Kinase Inhibitor Activity in Patients with NSCLC Harboring Uncommon EGFR Mutations: A Retrospective International Cohort Study (UpSwinG). Popat S; Hsia TC; Hung JY; Jung HA; Shih JY; Park CK; Lee SH; Okamoto T; Ahn HK; Lee YC; Sato Y; Lee SS; Mascaux C; Daoud H; Märten A; Miura S Oncologist; 2022 Apr; 27(4):255-265. PubMed ID: 35274704 [TBL] [Abstract][Full Text] [Related]
5. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors. Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M; Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527 [TBL] [Abstract][Full Text] [Related]
6. Clinical Activity of Afatinib in Patients With Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Spanish Retrospective Multicenter Study. Moran T; Taus A; Arriola E; Aguado C; Dómine M; Rueda AG; Calles A; Cedrés S; Viñolas N; Isla D; Palmero R; Sereno M; Diaz V; Juan O; Marsé R; Martorell PM; Sánchez Torres JM; Clin Lung Cancer; 2020 Sep; 21(5):428-436.e2. PubMed ID: 32461037 [TBL] [Abstract][Full Text] [Related]
7. An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations. Park K; Kim JS; Kim JH; Kim YC; Kim HG; Cho EK; Jin JY; Kim M; Märten A; Kang JH BMC Cancer; 2021 Jul; 21(1):802. PubMed ID: 34253172 [TBL] [Abstract][Full Text] [Related]
8. Afatinib treatment response in advanced lung adenocarcinomas harboring uncommon mutations. Li T; Wang S; Ying J; Wang Y; Hu X; Hao X; Xu Z; Xing P; Li J Thorac Cancer; 2021 Nov; 12(21):2924-2932. PubMed ID: 34549528 [TBL] [Abstract][Full Text] [Related]
9. All EGFR mutations are (not) created equal: focus on uncommon EGFR mutations. Ullas B; Shrinidhi N; Mansi S; Narayan S; Parveen J; Surender D; Joslia JT; Anurag M J Cancer Res Clin Oncol; 2023 Apr; 149(4):1541-1549. PubMed ID: 35581383 [TBL] [Abstract][Full Text] [Related]
10. Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan. Hsu PC; Lee SH; Chiu LC; Lee CS; Wu CE; Kuo SC; Ju JS; Huang AC; Li SH; Ko HW; Yang CT; Wang CC Target Oncol; 2023 Mar; 18(2):195-207. PubMed ID: 36805452 [TBL] [Abstract][Full Text] [Related]
11. Successful Treatment of a Patient with Lung Adenocarcinoma Harboring Compound EGFR Gene Mutations, G719X and S768I, with Afatinib. Kutsuzawa N; Takahashi F; Tomomatsu K; Obayashi S; Takeuchi T; Takihara T; Hayama N; Oguma T; Aoki T; Asano K Tokai J Exp Clin Med; 2020 Sep; 45(3):113-116. PubMed ID: 32901897 [TBL] [Abstract][Full Text] [Related]
14. Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis. Wang C; Zhao K; Hu S; Dong W; Gong Y; Xie C Oncologist; 2023 Jun; 28(6):e397-e405. PubMed ID: 37116899 [TBL] [Abstract][Full Text] [Related]
15. Unveiling the Landscape of Uncommon EGFR Mutations in NSCLC-A Systematic Review. Borgeaud M; Parikh K; Banna GL; Kim F; Olivier T; Le X; Addeo A J Thorac Oncol; 2024 Jul; 19(7):973-983. PubMed ID: 38499147 [TBL] [Abstract][Full Text] [Related]
16. Effectiveness and Tolerability of First-Line Afatinib for Advanced EGFR-Mutant Non-Small Cell Lung Cancer in Vietnam. Vu TH; Nguyen HTT; Dao LK; Duong CK; Nguyen CV; Doan TT; Nguyen HTT; Hoang HH; Dinh DK; Le GV; Vu TT; Truong MC; Nguyen LT Asian Pac J Cancer Prev; 2021 May; 22(5):1581-1590. PubMed ID: 34048189 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X/L861Q/S768I. Pang LL; Gan JD; Tan JR; Huang YH; Liao J; Liang WT; Deng PB; Fang WF Cancer; 2022 Nov; 128(21):3804-3814. PubMed ID: 36069292 [TBL] [Abstract][Full Text] [Related]
18. First-Line Osimertinib for Previously Untreated Patients With NSCLC and Uncommon EGFR Mutations: The UNICORN Phase 2 Nonrandomized Clinical Trial. Okuma Y; Kubota K; Shimokawa M; Hashimoto K; Kawashima Y; Sakamoto T; Wakui H; Murakami S; Okishio K; Hayashihara K; Ohe Y; JAMA Oncol; 2024 Jan; 10(1):43-51. PubMed ID: 37991747 [TBL] [Abstract][Full Text] [Related]
19. Afatinib in EGFR TKI-Naïve Patients with Locally Advanced or Metastatic EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Pooled Analysis of Three Phase IIIb Studies. Passaro A; de Marinis F; Tu HY; Laktionov KK; Feng J; Poltoratskiy A; Zhao J; Tan EH; Gottfried M; Lee V; Kowalski D; Yang CT; Srinivasa BJ; Clementi L; Jalikop T; Huang DCL; Cseh A; Park K; Wu YL Front Oncol; 2021; 11():709877. PubMed ID: 34307179 [TBL] [Abstract][Full Text] [Related]
20. Sensitivities to various epidermal growth factor receptor-tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor-tyrosine kinase inhibitor? Banno E; Togashi Y; Nakamura Y; Chiba M; Kobayashi Y; Hayashi H; Terashima M; de Velasco MA; Sakai K; Fujita Y; Mitsudomi T; Nishio K Cancer Sci; 2016 Aug; 107(8):1134-40. PubMed ID: 27240419 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]